These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 32250264)

  • 1. Vitiligo-like lesions developing upon immune checkpoint inhibition in advanced melanoma.
    Grän F; Emmerich K; Mohme S; Goebeler M; Gesierich A
    Eur J Dermatol; 2020 Feb; 30(1):72-73. PubMed ID: 32250264
    [No Abstract]   [Full Text] [Related]  

  • 2. [Vitiligo under checkpoint inhibitors].
    Amini-Adle M; Dalle S
    Ann Dermatol Venereol; 2018 Oct; 145(10):633-635. PubMed ID: 29866472
    [No Abstract]   [Full Text] [Related]  

  • 3. Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients.
    Nardin C; Jeand'heur A; Bouiller K; Valnet-Rabier MB; Dresco F; Castagna J; Mareschal A; Carlet C; Nerich V; Limat S; Puzenat E; Aubin F
    J Am Acad Dermatol; 2020 Mar; 82(3):770-772. PubMed ID: 31734192
    [No Abstract]   [Full Text] [Related]  

  • 4. Sarcoid-like reaction and vitiligo occurring after nivolumab therapy in a patient with metastatic melanoma.
    Fukuchi K; Hikawa M; Sano Y; Kasuya A; Aoshima M; Tatsuno K; Nakamura Y; Kosugi I; Tokura Y
    J Dermatol; 2019 Oct; 46(10):e359-e360. PubMed ID: 30985014
    [No Abstract]   [Full Text] [Related]  

  • 5. The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies.
    Wu CE; Yang CK; Peng MT; Huang PW; Chang CF; Yeh KY; Chen CB; Wang CL; Hsu CW; Chen IW; Lin CT; Ueng SH; Lin G; Lin YF; Cheng CY; Chang JW
    BMC Cancer; 2020 Oct; 20(1):1018. PubMed ID: 33087090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study.
    Nakano E; Takahashi A; Namikawa K; Muto Y; Jinnai S; Kage Y; Mizuta H; Tsutsumida A; Yamazaki N
    J Dermatol; 2020 Jun; 47(6):622-628. PubMed ID: 32162349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study.
    Matsuya T; Nakamura Y; Matsushita S; Tanaka R; Teramoto Y; Asami Y; Uehara J; Aoki M; Yamamura K; Nakamura Y; Fujisawa Y; Livingstone E; Zimmer L; Schadendorf D; Kagamu H; Fujimoto M; Honma M; Ishida-Yamamoto A; Araki R; Yamamoto A
    J Dermatol; 2020 Jun; 47(6):629-635. PubMed ID: 32275100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on the safety of nivolumab for the treatment of advanced melanoma.
    Czarnecka AM; Rutkowski P
    Expert Opin Drug Saf; 2020 Apr; 19(4):409-421. PubMed ID: 32293935
    [No Abstract]   [Full Text] [Related]  

  • 9. Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma.
    Yoshida S; Shiraishi K; Mito T; Sayama K
    Clin Exp Dermatol; 2020 Oct; 45(7):908-911. PubMed ID: 32394515
    [No Abstract]   [Full Text] [Related]  

  • 10. Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.
    Fukumoto T; Horita N
    Eur J Cancer; 2021 Apr; 147():140-141. PubMed ID: 33662688
    [No Abstract]   [Full Text] [Related]  

  • 11. Case of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab in a patient with advanced malignant melanoma.
    Wada N; Uchi H; Furue M
    J Dermatol; 2017 Aug; 44(8):e196-e197. PubMed ID: 28391613
    [No Abstract]   [Full Text] [Related]  

  • 12. Genital lichen sclerosus after nivolumab.
    Miraglia E; Soda G; Giustini S
    Dermatol Online J; 2020 Nov; 26(11):. PubMed ID: 33342187
    [No Abstract]   [Full Text] [Related]  

  • 13. Immune checkpoint inhibitors and pre-existing antinuclear antibodies: the rheumatologist point of view.
    Ceccarelli F; Botticelli A; Natalucci F; Olivieri G; Cirillo A; Alessandri C; Marchetti P; Conti F
    Clin Transl Oncol; 2021 Sep; 23(9):1961-1962. PubMed ID: 33728870
    [No Abstract]   [Full Text] [Related]  

  • 14. Nivolumab-induced multiple morphea associated with eosinophilic fasciitis.
    Lacombe M; Bedane C; Delaumenie S; Bernard P
    Eur J Dermatol; 2021 Dec; 31(6):844-846. PubMed ID: 34911674
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute renal transplant rejection following nivolumab therapy for metastatic melanoma.
    Tan B; Baxter M; Casasola R
    BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33558380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion.
    Lommerts JE; Bekkenk MW; Luiten RM
    Expert Opin Drug Saf; 2021 Aug; 20(8):883-888. PubMed ID: 33896329
    [No Abstract]   [Full Text] [Related]  

  • 17. Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma.
    Gambichler T; Seifert C; Lehmann M; Lukas C; Scheel C; Susok L
    Immunotherapy; 2020 May; 12(7):439-444. PubMed ID: 32308086
    [No Abstract]   [Full Text] [Related]  

  • 18. Immune checkpoint inhibitor-induced granulomatosis with polyangiitis.
    Hung W; Cusnir I; Habib S; Smylie M; Solez K; Yacyshyn E
    Rheumatology (Oxford); 2021 Jun; 60(6):e190-e191. PubMed ID: 33367837
    [No Abstract]   [Full Text] [Related]  

  • 19. A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.
    Belkaid S; Berger M; Nouvier M; Picard C; Dalle S
    Eur J Cancer; 2020 Nov; 139():169-172. PubMed ID: 32992155
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of endocrine immune-related adverse events and improved survival in advanced melanoma patients treated with nivolumab monotherapy.
    Maeda T; Yoshino K; Nagai K; Oaku S; Kato M; Hiura A; Hata H
    Eur J Cancer; 2019 Jul; 115():13-16. PubMed ID: 31082687
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.